F
Financials.page
Company Fundamentals
Workspace
OverviewhomeCompaniesdirectoryAPI & MCPdevelopers
Company financial data, refreshed daily. Not investment advice.
Financials.page — company financial data, refreshed daily. Not investment advice. Legal & terms
Annual figures as reported in 10-K / 20-F / 40-F filings.
GTBP · CIK 0000109657

GT BIOPHARMA, INC.

Annual figures as reported, FY2014–FY2025. Ratios and growth rates derived on-page.

GTBP logo
Pharmaceutical Preparations
Company profile
Nasdaq · GTBPHQ San Francisco, CAIncorporated in DEFiscal year ends Dec 31Non-accelerated filer Smaller reporting company
Net income
−$28.4M
▼ −115.4% vs FY2024
Operating cash flow
−$12.9M
▼ −0.1% vs FY2024
Diluted EPS
−$6.68
▲ +3.7% vs FY2024

Net income

Losses shown in terracotta

−200M−100M0’14’16’18’20’22’24’25−$28.4M

Recent quarters

momentum · last 12 quarters
Net income — Mar ’26 quarter
−$2.8M
▼ −265.1% vs Mar ’25
Diluted EPS — trailing 12 months
−$6.46
▼ −14.7% vs Mar ’25

Quarterly net income

Losses shown in terracotta

−30M−20M−10M0Jun ’23Dec ’23Jun ’24Dec ’24Jun ’25Dec ’25Mar ’26−$2.8M
QuarterRevenueRev. YoYGross marginNet incomeNet marginDiluted EPS
Mar ’26———−$2.8M—−$0.11
Dec ’25———−$5.7M—$3.53
Sep ’25———$8.3M—$1.04
Jun ’25———−$30.2M—−$10.92
Mar ’25———−$776K—−$0.33
Dec ’24———−$3.8M—−$1.60
Sep ’24———−$3.4M—−$1.53
Jun ’24———−$3.7M—−$2.17

Profitability & returns

quality of earnings

Returns on capital

Net income vs year-end equity and assets

0%20000%’16’18’20’22’24
Return on equityReturn on assets

Cash flow

cash generation

Operating cash flow

Net cash from operations

−15M−10M−5M0’14’16’18’20’22’24’25−$12.9M

Shareholder returns

capital allocation

Capital returned

Cash paid out as dividends and share repurchases

0100K200K’25
Dividends paid

Diluted shares outstanding

Falling count means buybacks outpace dilution

02M4M’15’17’19’21’23’256M

Balance sheet

financial position

Stockholders’ equity

At fiscal year end

−20M020M’18’20’22’24’25−$25.9M

Growth rates

compounding, annualized
Share count change (split-adjusted)
+3671.7%
5y
+6807.3%
10y

Key ratios

derived per fiscal year
Fiscal yearROEROACurrent ratio
FY2025—−398.0%3.50×
FY2024—−311.0%0.72×
FY2023−101.6%−53.8%2.12×
FY2022−178.0%−124.8%3.35×
FY2021−264.8%−180.3%3.14×
FY2020—−499.8%0.16×
FY2019—−9759.3%0.01×
FY2018−2279.6%−1020.5%0.01×
FY2017—−56.7%0.22×
FY2016—39072.0%0.00×
FY2015——0.00×
FY2014——0.03×

Annual figures

as reported
Fiscal yearRevenueGross profitOp. incomeNet incomeDiluted EPSOp. cash flowCapexTotal assetsLiabilitiesEquityCashLT debt
FY2025——−$12.4M−$28.4M−$6.68−$12.9M—$7.1M$31.0M−$25.9M$6.8M—
FY2024——−$14.4M−$13.2M−$6.94−$12.9M—$4.2M$5.9M−$1.7M$4.0M—
FY2023——−$13.6M−$7.6M−$5.64−$8.9M—$14.1M$6.6M$7.5M$1.1M—
FY2022——−$21.3M−$20.9M−$19.66−$15.2M—$16.7M$5.0M$11.7M$5.7M—
FY2021——−$57.5M−$58.0M−$61.80−$15.6M—$32.2M$10.3M$21.9M$9.0M—
FY2020——−$6.8M−$28.3M−$193.50−$7.3M—$5.7M$33.2M−$27.5M$5.3M—
FY2019——$16.1M−$38.6M−$0.30−$3.7M—$396K$19.7M−$19.3M$28K—
FY2018——−$250.1M−$259.2M−$154.80−$10.7M—$25.4M$14.0M$11.4M$60K—
FY2017——−$135.6M−$144.2M−$258.00−$5.4M—$254.4M$2.7M—$576K—
FY2016——−$9.4M$9.8M$3597.30−$1.9M—$25K$18.9M—$19K—
FY2015——−$8.9M−$21.5M−$268.80−$4.7M——$50.6M—$47K—
FY2014——−$2.4M−$23.5M−$1.20−$1.7M——$30.5M—$855K—

Latest filings

the most recent regulatory filings
DEF 14AProxy statement2026-07-02 ↗PRE 14ASEC filing2026-06-18 ↗8-KCurrent report — material event2026-06-12 ↗8-KCurrent report — material event2026-05-22 ↗10-QQuarterly report2026-05-15 ↗EFFECTSEC filing2026-05-13 ↗424B3Prospectus2026-05-13 ↗S-1Securities registration2026-04-30 ↗8-KCurrent report — material event2026-04-07 ↗10-Q/AQuarterly report2026-03-06 ↗

Company logos by Elbstream and unavatar.

All third-party trademarks, service marks, logos, and brand names used on this site are the property of their respective owners. The use of these logos is for identification and illustrative purposes only and does not imply any affiliation, sponsorship, or endorsement by the respective owners.